Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 28, 2025
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Journal: Therapeutic advances in medical oncology
Published: May 21, 2024
Second-line lenvatinib in patients with recurrent endometrial cancer.
Journal: Gynecologic oncology
Published: December 03, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Journal: Gynecologic oncology
Published: September 03, 2019
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 23, 2016
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 16, 2013
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 25, 2012
Showing 1-7 of 7
Last Updated: 09/26/2026